Base de dados : MEDLINE
Pesquisa : D08.811.277.656.300.760.635.075 [Categoria DeCS]
Referências encontradas : 419 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 42 ir para página                         

  1 / 419 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26108037
[Au] Autor:Patel D; Haque A; Gao Y; Revzin A
[Ad] Endereço:Department of Biomedical Engineering, University of California, Davis, 451 East Health Sciences St. #2619, Davis, CA, USA. arevzin@ucdavis.edu.
[Ti] Título:Using reconfigurable microfluidics to study the role of HGF in autocrine and paracrine signaling of hepatocytes.
[So] Source:Integr Biol (Camb);7(7):815-24, 2015 Jul.
[Is] ISSN:1757-9708
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Cancer, developmental biology and tissue injury present multiple examples where groups of cells residing in close proximity communicate via paracrine factors. It is nearly impossible to dissect such cellular interactions in vivo and is quite challenging in vitro. The goal of this study is to utilize a reconfigurable microfluidic device in order to study paracrine signal exchange between groups of primary hepatocytes in vitro. Previously, we demonstrated that hepatocytes residing on protein spots containing collagen and hepatocyte growth factor (HGF) spots expressed epithelial (hepatic) phenotypes and also rescued them in neighboring hepatocytes on collagen spots that did not receive direct HGF stimulus. Herein, we designed a microfluidic device with parallel fluidic channels separated by retractable (reconfigurable) walls and employed this device to investigate interactions between groups of HGF-stimulated and unstimulated hepatocytes. Using a novel reconfigurable microfluidic device, we demonstrate that cultivation of HGF-containing protein spots upregulates the production of endogenous HGF in hepatocytes and that these HGF molecules diffuse over, causing phenotype enhancement in the recipient cells. We also show that selective treatment of the recipient hepatocytes with a c-met inhibitor (SU11274) diminishes the rescue effect, as gauged by the down-regulation of albumin and HGF expression. Our study is one of the first to demonstrate paracrine signaling via HGF in primary hepatocytes. More broadly, tools and methods described here may be used to study paracrine signaling in other types of cells and will have relevance for various fields of biomedical research from cancer to immunology.
[Mh] Termos MeSH primário: Comunicação Autócrina/fisiologia
Separação Celular/instrumentação
Análise de Injeção de Fluxo/instrumentação
Hepatócitos/fisiologia
Dispositivos Lab-On-A-Chip
Comunicação Parácrina/fisiologia
[Mh] Termos MeSH secundário: Animais
Anistreplase
Células Cultivadas
Desenho de Equipamento
Análise de Falha de Equipamento
Feminino
Hepatócitos/citologia
Ratos
Ratos Endogâmicos Lew
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
81669-57-0 (Anistreplase)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150625
[St] Status:MEDLINE
[do] DOI:10.1039/c5ib00105f


  2 / 419 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25715964
[Au] Autor:Gilmour KM; Iversen L; Hannaford PC
[Ad] Endereço:School of Medicine & Dentistry and.
[Ti] Título:Long-term survival benefits of thrombolysis: the Royal College of General Practitioners' myocardial infarction study.
[So] Source:Fam Pract;32(2):192-7, 2015 Apr.
[Is] ISSN:1460-2229
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To investigate whether there is a long-term survival benefit from receipt of thrombolysis in routine care particularly pre-hospital thrombolysis, using 20 year mortality data from the RCGP myocardial infarction (MI) cohort study. METHODS: During 1991-92 the RCGP MI study assessed GP delivery of thrombolysis. Participants who received pre-hospital thrombolysis (n = 290), thrombolysis in hospital (n = 781) or no thrombolysis (n = 2021) were followed and mortality data collected to June 2012. The relationship between thrombolysis and survival time was analysed using Cox regression at 28 days, 1, 5, 10, 15 years post-AMI, and at end of follow-up (~20 years post-AMI). RESULTS: Compared to those who did not receive it, participants who received thrombolysis had a significant survival benefit at 28 days [adjusted hazard ratio (HR) 0.72, 95% confidence interval (CI): 0.58-0.90]; 1 year (adjusted HR 0.69, 95% CI: 0.57-0.83); 5 years (adjusted HR 0.76, 95% CI: 0.66-0.86); 10 years (adjusted HR 0.85, 95% CI: 0.77-0.95) and 15 years (adjusted HR 0.88, 95% CI: 0.80-0.96) post-AMI until end of follow-up (adjusted HR 0.92, 95% CI: 0.84-1.00). Pre versus in-hospital thrombolysis did not appear beneficial, although there was evidence among the pre-hospital group that short symptom onset-to-needle times conferred greater benefit. CONCLUSIONS: We found substantial long-term survival benefits associated with thrombolysis when used in routine care. Although primary percutaneous coronary intervention (pPCI) is now the choice treatment, thrombolysis remains an important option when pPCI cannot be delivered within 120 minutes of diagnosis.
[Mh] Termos MeSH primário: Anistreplase/uso terapêutico
Fibrinolíticos/uso terapêutico
Medicina Geral
Infarto do Miocárdio/tratamento farmacológico
Infarto do Miocárdio/mortalidade
Terapia Trombolítica
[Mh] Termos MeSH secundário: Idoso
Dor no Peito/etiologia
Serviços Médicos de Emergência
Feminino
Seres Humanos
Masculino
Meia-Idade
Infarto do Miocárdio/complicações
Estudos Prospectivos
Taxa de Sobrevida
Fatores de Tempo
Tempo para o Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Fibrinolytic Agents); 81669-57-0 (Anistreplase)
[Em] Mês de entrada:1601
[Cu] Atualização por classe:150325
[Lr] Data última revisão:
150325
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150227
[St] Status:MEDLINE
[do] DOI:10.1093/fampra/cmv006


  3 / 419 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:17328339
[Au] Autor:Bayram B; Kupnik M; Yaralioglu GG; Oralkan O; Ergun AS; Lin DS; Wong SH; Khuri-Yakub BT
[Ad] Endereço:Edward L. Ginzton Laboratory, Stanford University, CA 94305, USA. bbayram@gmail.com
[Ti] Título:Finite element modeling and experimental characterization of crosstalk in 1-D CMUT arrays.
[So] Source:IEEE Trans Ultrason Ferroelectr Freq Control;54(2):418-30, 2007 Feb.
[Is] ISSN:0885-3010
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Crosstalk is the coupling of energy between the elements of an ultrasonic transducer array. This coupling degrades the performance of transducers in applications such as medical imaging and therapeutics. In this paper, we present an experimental demonstration of guided interface waves in capacitive micromachined ultrasonic transducers (CMUTs). We compare the experimental results to finite element calculations using a commercial package (LS-DYNA) for a 1-D CMUT array operating in the conventional and collapsed modes. An element in the middle of the array was excited with a unipolar voltage pulse, and the displacements were measured using a laser interferometer along the center line of the array elements immersed in soybean oil. We repeated the measurements for an identical CMUT array covered with a 4.5-microm polydimethylsiloxane (PDMS) layer. The main crosstalk mechanism is the dispersive guided modes propagating in the fluid-solid interface. Although the transmitter element had a center frequency of 5.8 MHz with a 130% fractional bandwidth in the conventional operation, the dispersive guided mode was observed with the maximum amplitude at a frequency of 2.1 MHz, and had a cut-off frequency of 4 MHz. In the collapsed operation, the dispersive guided mode was observed with the maximum amplitude at a frequency of 4.0 MHz, and had a cut-off frequency of 10 MHz. Crosstalk level was lower in the collapsed operation (-39 dB) than in the conventional operation (-24.4 dB). The coverage of the PDMS did not significantly affect the crosstalk level, but reduced the phase velocity for both operation modes. Lamb wave modes, A0 and S0, were also observed with crosstalk levels of -40 dB and -65 dB, respectively. We observed excellent agreement between the finite element and the experimental results.
[Mh] Termos MeSH primário: Aumento da Imagem/métodos
Interpretação de Imagem Assistida por Computador/métodos
Modelos Teóricos
Transdutores
Ultrassonografia/instrumentação
[Mh] Termos MeSH secundário: Anistreplase
Simulação por Computador
Projeto Auxiliado por Computador
Análise de Elementos Finitos
Ultrassonografia/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
81669-57-0 (Anistreplase)
[Em] Mês de entrada:0703
[Cu] Atualização por classe:071203
[Lr] Data última revisão:
071203
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:070303
[St] Status:MEDLINE


  4 / 419 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:16275118
[Au] Autor:Baruah DB; Dash RN; Chaudhari MR; Kadam SS
[Ad] Endereço:Department of Quality Assurance Techniques, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Erandwane, Pune-411038, India.
[Ti] Título:Plasminogen activators: a comparison.
[So] Source:Vascul Pharmacol;44(1):1-9, 2006 Jan.
[Is] ISSN:1537-1891
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Thrombolytic drugs play a crucial role in the management of patients with acute myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis, acute thrombosis of retinal vessel, extensive coronary emboli, and peripheral vascular thromboembolism. Recognition of the importance of fibrinolytic system in thrombus resolution has resulted in the development of different fibrinolytic agents. Now a days several newer plasminogen activators with different pharmacokinetic and pharmacodynamic properties have been developed to treat thrombotic disease, which are fibrin specific with prolonged half-life and can be administered as a single bolus.
[Mh] Termos MeSH primário: Fibrinolíticos/farmacocinética
Ativadores de Plasminogênio/farmacocinética
[Mh] Termos MeSH secundário: Anistreplase/administração & dosagem
Anistreplase/farmacocinética
Anistreplase/uso terapêutico
Doenças Cardiovasculares/tratamento farmacológico
Vias de Administração de Medicamentos
Esquema de Medicação
Fibrinolíticos/administração & dosagem
Fibrinolíticos/uso terapêutico
Seres Humanos
Metaloendopeptidases/administração & dosagem
Metaloendopeptidases/farmacocinética
Metaloendopeptidases/uso terapêutico
Ativadores de Plasminogênio/administração & dosagem
Ativadores de Plasminogênio/uso terapêutico
Guias de Prática Clínica como Assunto
Estreptoquinase/administração & dosagem
Estreptoquinase/farmacocinética
Estreptoquinase/uso terapêutico
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Fibrinolytic Agents); 81669-57-0 (Anistreplase); EC 3.4.- (Streptokinase); EC 3.4.21.- (Plasminogen Activators); EC 3.4.24.- (Metalloendopeptidases); EC 3.4.24.29 (auR protein, Staphylococcus aureus)
[Em] Mês de entrada:0604
[Cu] Atualização por classe:071115
[Lr] Data última revisão:
071115
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:051109
[St] Status:MEDLINE


  5 / 419 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15557913
[Au] Autor:Ouriel K; Kaul AF; Leonard MC
[Ad] Endereço:Department of Vascular Surgery, Cleveland Clinic Foundation, OH 44195, USA. ourielk@ccf.org
[Ti] Título:Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis.
[So] Source:J Vasc Surg;40(5):971-7, 2004 Nov.
[Is] ISSN:0741-5214
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Over the past 2 decades the use of thrombolytic therapy in the management of peripheral occlusive diseases, most notably peripheral arterial occlusion (PAO) and deep venous thrombosis (DVT), has become an accepted and potentially preferable alternative to surgery. We examined the period when urokinase was in short supply and subsequently unavailable, to explore potential differences in clinical outcome and economic effect between urokinase and recombinant tissue plasminogen activator (rt-PA). MATERIAL AND METHODS: Data were obtained from the Premier Perspective Database, a broad clinical database that contains information on inpatient medical practices and resource use. The study population included all patients hospitalized in 1999 and 2000 with a primary or secondary diagnosis of PAO or DVT. Incidence was calculated for common adverse events, including bleeding complications, intracranial hemorrhage, amputation, and death. Cost data were also abstracted from the database, and are expressed as mean +/- SD. RESULTS: Demographic variables were similar in the urokinase and rt-PA groups. The rate of bleeding complications was similar in the urokinase and rt-PA groups. There were no intracranial hemorrhages in the urokinase group, compared with a rate of 1.5% in the rt-PA PAO group (P = .087) and 1.9% in the rt-PA DVT group (P = .175). The in-hospital mortality rate was lower in the urokinase-treated PAO subgroup (3.6% vs 8.5%; P = .026), but a similar finding in the DVT subgroup did not achieve statistical significance (4% vs 9.8%; P = .069). While pharmacy costs were greater in the urokinase-treated group (US 5472 dollars +/- US 5579 dollars vs US 3644 dollars +/- US 6009 dollars, P < .001; PAO subgroup, US 11,070 dollars +/- US 15,409 dollars vs US 6150 dollars +/- US 12,398 dollars, P = .003), overall hospital costs did not differ significantly between the 2 groups. This finding appears to be explained by a shorter hospital stay and reduced room and board costs in the urokinase-treated group. CONCLUSION: There were significant differences in outcome in patients with PAO and DVT who received treatment with urokinase and rt-PA. While pharmacy costs were significantly greater when urokinase was used, reduction in length of stay accounted for similar total hospital costs compared with rt-PA. These findings must be considered in the context of the retrospective nature of the analysis and the potential to use dosing regimens that differ from those in this study.
[Mh] Termos MeSH primário: Arteriopatias Oclusivas/tratamento farmacológico
Arteriopatias Oclusivas/economia
Custos Hospitalares
Terapia Trombolítica/métodos
Trombose Venosa/tratamento farmacológico
Trombose Venosa/economia
[Mh] Termos MeSH secundário: Anistreplase/uso terapêutico
Estudos de Coortes
Análise Custo-Benefício
Feminino
Seguimentos
Seres Humanos
Tempo de Internação
Masculino
Doenças Vasculares Periféricas/tratamento farmacológico
Doenças Vasculares Periféricas/economia
Probabilidade
Sistema de Registros
Medição de Risco
Índice de Gravidade de Doença
Resultado do Tratamento
Ativador de Plasminogênio Tipo Uroquinase/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
81669-57-0 (Anistreplase); EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
[Em] Mês de entrada:0412
[Cu] Atualização por classe:121003
[Lr] Data última revisão:
121003
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:041124
[St] Status:MEDLINE


  6 / 419 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
[PMID]:15505262
[Au] Autor:Bogaty P; Buller CE; Dorian P; O'Neill BJ; Armstrong PW; Canadian Cardiovascular Society Working Group
[Ad] Endereço:Quebec Heart Institute, Laval Hospital, Sainte-Foy.
[Ti] Título:Applying the new STEMI guidelines: 1. Reperfusion in acute ST-segment elevation myocardial infarction.
[So] Source:CMAJ;171(9):1039-41, 2004 Oct 26.
[Is] ISSN:0820-3946
[Cp] País de publicação:Canada
[La] Idioma:eng
[Mh] Termos MeSH primário: Eletrocardiografia
Fidelidade a Diretrizes
Infarto do Miocárdio/diagnóstico
Infarto do Miocárdio/tratamento farmacológico
Terapia Trombolítica/normas
[Mh] Termos MeSH secundário: Anistreplase/administração & dosagem
Canadá
Relação Dose-Resposta a Droga
Esquema de Medicação
Quimioterapia Combinada
Feminino
Seres Humanos
Infusões Intravenosas
Meia-Idade
Reperfusão Miocárdica/normas
Medição de Risco
Índice de Gravidade de Doença
Estreptoquinase/uso terapêutico
Terapia Trombolítica/efeitos adversos
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
81669-57-0 (Anistreplase); EC 3.4.- (Streptokinase)
[Em] Mês de entrada:0412
[Cu] Atualização por classe:140608
[Lr] Data última revisão:
140608
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:041027
[St] Status:MEDLINE


  7 / 419 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15362930
[Au] Autor:Vale L; Steffens H; Donaldson C
[Ad] Endereço:Health Economics Research Unit, University of Aberdeen, Aberdeen AB25 2ZD, Scotland. l.vale@abdn.ac.uk
[Ti] Título:The costs and benefits of community thrombolysis for acute myocardial infarction : a decision-analytic model.
[So] Source:Pharmacoeconomics;22(14):943-54, 2004.
[Is] ISSN:1170-7690
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: There is evidence that the earlier a patient reaches hospital and receives thrombolysis, the better the outcome. The GREAT (Grampian Region Early Anistreplase Trial) directly addressed the issue of early thrombolysis by evaluating, in a randomised controlled trial, the efficacy of thrombolysis in the community compared with that administered in hospital. OBJECTIVE: This paper aimed to model the cost and benefits of community compared with hospital thrombolysis from the UK NHS perspective, using efficacy data from the GREAT. METHODS: A decision-analytic approach was used to model these two alternatives. Resource use and cost estimates were estimated for a single tertiary centre. Estimates of effectiveness in life-years were obtained from the 4-year follow-up for patients recruited to the GREAT, using declining exponential approximation of life expectancy. Costs are in pounds sterling, 2000/1 values. RESULTS: Community thrombolysis had an average life expectancy of 12.48 years and hospital thrombolysis had an average life expectancy of 12.39 years. Costs were 361 pounds sterling for community thrombolysis and 300 pounds sterling for hospital thrombolysis. Community thrombolysis led to an additional 0.09 years of life-expectancy gained compared with hospital thrombolysis at an additional cost of 61 pounds sterling per patient. Therefore, the incremental cost per life-year gained for the community thrombolysis service over the hospital thrombolysis service was 667 pounds sterling. Sensitivity analysis showed that estimates of cost per life-year gained were most sensitive to the estimates of survival. CONCLUSION: This model suggests that, from the UK NHS perspective, implementing community thrombolysis may lead to extra survival but at extra cost over hospital thrombolysis. Although the incremental cost per life-year is modest, judgements still have to be made, however, as to whether the extra benefits estimated are worth the additional resources required. This requires consideration of the local context in which the service may be introduced.
[Mh] Termos MeSH primário: Fibrinolíticos/uso terapêutico
Infarto do Miocárdio/economia
Terapia Trombolítica/economia
[Mh] Termos MeSH secundário: Anistreplase/economia
Anistreplase/uso terapêutico
Institutos de Cardiologia
Estudos de Coortes
Serviços de Saúde Comunitária
Análise Custo-Benefício
Técnicas de Apoio para a Decisão
Custos de Medicamentos
Fibrinolíticos/economia
Heparina/economia
Heparina/uso terapêutico
Hospitalização
Seres Humanos
Infarto do Miocárdio/tratamento farmacológico
Infarto do Miocárdio/mortalidade
Ensaios Clínicos Controlados Aleatórios como Assunto
Estreptoquinase/economia
Estreptoquinase/uso terapêutico
Análise de Sobrevida
Reino Unido
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Fibrinolytic Agents); 81669-57-0 (Anistreplase); 9005-49-6 (Heparin); EC 3.4.- (Streptokinase)
[Em] Mês de entrada:0411
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:040915
[St] Status:MEDLINE


  8 / 419 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:14660986
[Au] Autor:Waters RE; Mahaffey KW; Granger CB; Roe MT
[Ad] Endereço:Duke Clinical Research Institute, Durham, NC 27705, USA.
[Ti] Título:Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies.
[So] Source:Am Heart J;146(6):958-68, 2003 Dec.
[Is] ISSN:1097-6744
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The therapeutic approach to patients with acute ST-segment elevation myocardial infarction (STEMI) has advanced rapidly over the past decade. Intravenous fibrinolytic therapy remains the most common form of reperfusion therapy worldwide, since fibrinolytics are associated with a dramatic reduction in mortality rates. However, primary percutaneous coronary intervention (PCI) is associated with improved outcomes and less bleeding complications compared with fibrinolytic therapy, but it is not widely available. Adjunctive therapies with intracoronary stents, glycoprotein (GP) IIb/IIIa inhibitors, and more potent antithrombin agents have shown great promise for the initial treatment of STEMI and have stimulated further investigation of combined pharmacological/mechanical reperfusion strategies that may be synergistic. Although the optimal combination of fibrinolytics, antiplatelet agents, antithrombins, and mechanical reperfusion at hospitals with and without primary PCI facilities remains elusive, results from recent studies suggest that such a combined approach may facilitate transfer of patients with STEMI from a referral hospital to an invasive hospital for definitive primary PCI after administration of a potent pharmacologic regimen designed to enhance early infarct-related artery reperfusion. Thus, as the reperfusion era continues to evolve, the ideal treatment strategy for patients with STEMI is being redefined to integrate pharmacologic and mechanical approaches to reperfusion.
[Mh] Termos MeSH primário: Angioplastia Coronária com Balão
Trombose Coronária/tratamento farmacológico
Fibrinolíticos/uso terapêutico
Infarto do Miocárdio/terapia
Stents
Terapia Trombolítica
[Mh] Termos MeSH secundário: Anistreplase/uso terapêutico
Aspirina/uso terapêutico
Ensaios Clínicos como Assunto
Terapia Combinada
Trombose Coronária/complicações
Análise Custo-Benefício
Quimioterapia Combinada
Eletrocardiografia
Heparina/uso terapêutico
Seres Humanos
Infarto do Miocárdio/tratamento farmacológico
Infarto do Miocárdio/etiologia
Reperfusão Miocárdica/métodos
Complexo Glicoproteico GPIIb-IIIa de Plaquetas/antagonistas & inibidores
Proteínas Recombinantes/uso terapêutico
Estreptoquinase/uso terapêutico
Ativador de Plasminogênio Tecidual/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Fibrinolytic Agents); 0 (Platelet Glycoprotein GPIIb-IIIa Complex); 0 (Recombinant Proteins); 81669-57-0 (Anistreplase); 9005-49-6 (Heparin); DQA630RIE9 (reteplase); EC 3.4.- (Streptokinase); EC 3.4.21.68 (Tissue Plasminogen Activator); R16CO5Y76E (Aspirin); WGD229O42W (tenecteplase)
[Em] Mês de entrada:0401
[Cu] Atualização por classe:161124
[Lr] Data última revisão:
161124
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:031209
[St] Status:MEDLINE


  9 / 419 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:12947366
[Au] Autor:Lamfers EJ; Schut A; Hooghoudt TE; Hertzberger DP; Boersma E; Simoons ML; Verheugt FW
[Ad] Endereço:Department of Cardiology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands. ejp.lamfers@inter.nl.net
[Ti] Título:Prehospital thrombolysis with reteplase: the Nijmegen/Rotterdam study.
[So] Source:Am Heart J;146(3):479-83, 2003 Sep.
[Is] ISSN:1097-6744
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The objective of this observational study was to assess time from electrocardiogram diagnosis to treatment and time from pain onset to treatment with double bolus reteplase compared to current therapy with streptokinase or bolus anistreplase in 2 cities (Rotterdam and Nijmegen) in the Netherlands, where prehospital thrombolysis is an established way of treatment of acute myocardial infarction. METHODS: Prehospital thrombolysis is performed using electrocardiogram diagnosis by the ambulance service as well as bolus anistreplase for treatment in Nijmegen, and streptokinase infusion in Rotterdam. Reteplase or anistreplase/streptokinase was assigned open label to patients according to order of presentation on a 1-to-1 basis. All patients were treated with nitrates sublingually and aspirin orally. Time intervals were recorded by the ambulance staff. RESULTS: In total, 250 patients were treated between April 1, 1999 and August 1, 2000. Reteplase was used in 120 patients and anistreplase/streptokinase in 130 patients. Using double bolus reteplase resulted in a significantly shorter time to treatment: a median of 81 minutes compared to a median of 104 minutes with the established therapy (P <.0001). There were no differences in mortality, aborted myocardial infarction, hemorrhagic stroke or the need for rescue angioplasty between the groups. CONCLUSION: In prehospital thrombolysis, double bolus reteplase is associated with a shorter time to treatment than bolus anistreplase or infusion of streptokinase.
[Mh] Termos MeSH primário: Serviços Médicos de Emergência
Fibrinolíticos/uso terapêutico
Infarto do Miocárdio/tratamento farmacológico
Proteínas Recombinantes/uso terapêutico
Terapia Trombolítica
Ativador de Plasminogênio Tecidual/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Anistreplase/uso terapêutico
Feminino
Seres Humanos
Masculino
Meia-Idade
Infarto do Miocárdio/mortalidade
Países Baixos
Estatísticas não Paramétricas
Estreptoquinase/uso terapêutico
Fatores de Tempo
Grau de Desobstrução Vascular
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Fibrinolytic Agents); 0 (Recombinant Proteins); 81669-57-0 (Anistreplase); DQA630RIE9 (reteplase); EC 3.4.- (Streptokinase); EC 3.4.21.68 (Tissue Plasminogen Activator)
[Em] Mês de entrada:0310
[Cu] Atualização por classe:161124
[Lr] Data última revisão:
161124
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:030830
[St] Status:MEDLINE


  10 / 419 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
[PMID]:12695474
[Au] Autor:Rawles J; GREAT
[Ti] Título:GREAT: 10 year survival of patients with suspected acute myocardial infarction in a randomised comparison of prehospital and hospital thrombolysis.
[So] Source:Heart;89(5):563-4, 2003 May.
[Is] ISSN:1468-201X
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Anistreplase/uso terapêutico
Serviços Médicos de Emergência/estatística & dados numéricos
Fibrinolíticos/uso terapêutico
Hospitalização/estatística & dados numéricos
Infarto do Miocárdio/tratamento farmacológico
Terapia Trombolítica/métodos
[Mh] Termos MeSH secundário: Medicina de Família e Comunidade
Seres Humanos
Infarto do Miocárdio/mortalidade
Saúde da População Rural
Escócia/epidemiologia
Análise de Sobrevida
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; LETTER; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Fibrinolytic Agents); 81669-57-0 (Anistreplase)
[Em] Mês de entrada:0305
[Cu] Atualização por classe:140611
[Lr] Data última revisão:
140611
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:030416
[St] Status:MEDLINE



página 1 de 42 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde